Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-80.02M
Cash
151.3M
Avg Qtr Burn
-10.61M
Short % of Float
19.30%
Insider Ownership
14.65%
Institutional Own.
58.00%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Denifanstat w/ Bevacizumab Details Glioblastoma | Phase 3 Data readout | |
Phase 3 Data readout | ||
Denifanstat Details Metabolic-dysfunction Associated Steatohepatitis | Phase 3 Initiation | |
Denifanstat Details Non-alcoholic steatohepatitis | Phase 2 Update | |
Denifanstat Details Liver disease | Phase 1 Update | |
TVB-3567 Details Acne | Phase 1 Initiation |